Where all your ID needs are met! Sort of.
The ACTIVE trial! This is a phase III, RCT, double blind, multicenter, non-inferiority trial comparing isavuconazole vs caspofungin in invasive candidiasis. Folks, in ID, it doesn’t get any better than this (look at all these studies!) Exclusion criteria were Candida in any body part (i.e. osteomyelitis, IE, meningitis), severe immunodeficiency, >48hrs of other antifungal therapy.
This one is not groundbreaking but nice to have data supporting our decisions. This was a review of the literature evaluating the efficacy of cefazolin vs anti-staphylococcal penicillin (cloxacillin, nafcillin, flucoxacillin) in staph aureus bacteremia. The primary end point was 90d all cause mortality; secondary end point was 30d all cause mortality, treatment failure/relapse, and
This is a retrospective, observational cohort study from Detroit evaluating the frequency of IV to PO switch and the population for which this is use, as well as to figure out the factors associated with failure. They recruited 492 patients with MRSA bacteremia (basically anyone with the exception of polymicrobial bacteremia and those with wither
This is a cross-sectional and longitudinal assessment of BD glucan levels in 146 patients living with HIV. Within this cohort, 53 had been diagnosed within 6 months, 22 had chronic HIV but no ART, and 71 had chronic HIV and were on ART. These were then compared to 42 uninfected controls. The study design is
Retrospective study from South Korea evaluating the predictive value of BD glucan in the age of mold active triazole prophylaxis. They recruited patients that underwent induction chemotherapy, SCT, or GVHD treatment that had BD glucans throughout their stay while on posa or micafungin prophylaxis. They defined a positive BD glucan as 2 or more BDG
Dr. Germophile 